CD274 and small cell lung carcinoma: Another phase 3 multicenter clinical study, CAPSTONE-1, conducted in the Chinese population also confirmed that PD-L1 blocker combined with chemotherapy is superior to chemotherapy in improving median OS in initial untreated ES-SCLC patients (15.3 versus 12.8 months, p = 0.0017) (9).